<DOC>
	<DOCNO>NCT02333305</DOCNO>
	<brief_summary>We propose study Ataxia oculomotor apraxia type 1 ( AOA1 ) Coenzyme Q10 ( CoQ10 ) deficit observe . Main objective study : - To monitor evolution albumin patient affected AOA1 supplement CoQ10 ; - To measure clinical scale biological marker efficacy supplementation disease evolution . AOA1 characterise Hypoalbuminemia . Disease duration negatively correlate albumin level . This study aim understand mechanism disease hypothesis correction stabilization albumin level CoQ10 supplementation could impact disease evolution . The study plan 1 2 year supplementation . The CoQ10 classify food supplement already test neurological condition .</brief_summary>
	<brief_title>Evolution Albumin AOA1 Patients Supplemented With Coenzyme Q10</brief_title>
	<detailed_description>Ataxia ocular apraxia type 1 ( AOA1 ) autosomal recessive cerebellar ataxia . Patients ' phenotype associate early onset cerebellar ataxia , oculomotor apraxia , neuropathy often intellectual disability , hypoalbuminaemia hypercholesterolemia . APTX gene mutation responsible AOA1 disease identify family previously report ataxia Coenzyme Q10 deficiency . Therefore measured muscle Coenzyme Q10 six patient AOA1 find decreased level five . Hypercholesterolaemia low albumin level represent hallmark disease . We thus propose therapeutic trial Coenzyme Q10 AOA1 patient , use albumin evolution primary endpoint . Moreover several secondary endpoint perform : - clinical examination ( SARA scale ) - quantitative assessment ataxia ( calculation Composite Cerebellar Functional Severity CCFS ) - biological criterion ( prealbumin , cholesterol , alphafoetoprotein , blood count , hepatic checkup ) - oculographic examination . The study multicentric randomise placebo control trial two-year follow-up : - first year , one group supplement Coenzyme Q10 group receive placebo ; - second year , patient supplement Coenzyme Q10 order ass long term safety tolerance treatment .</detailed_description>
	<mesh_term>Ataxia</mesh_term>
	<mesh_term>Apraxias</mesh_term>
	<mesh_term>Cogan Syndrome</mesh_term>
	<mesh_term>Cerebellar Ataxia</mesh_term>
	<mesh_term>Hypoalbuminemia</mesh_term>
	<mesh_term>Coenzyme Q10</mesh_term>
	<mesh_term>Ubiquinone</mesh_term>
	<criteria>Inclusion criterion : 1 . Diagnosis ataxia oculomotor apraxia type I ( AOA1 ) confirm genetic molecular analysis 2 . Age â‰¥ 18 year 3 . Hypoalbuminemia 4 . Efficient contraception woman childbearing potential ( pregnancy test visit ) 5 . Signature write informed consent form 6 . Presence support person ( patient cognitive disorder ) Exclusion criterion : 1 . Hypersensitivity one excipients ( glycerin , ethanol , lecithin ) 2 . Absence hypoalbuminemia 3 . During 2 month inclusion : Use CoQ10 Treatment antioxidant ( vitamin C ) statins Use drug affect mitochondrial activity Anticholesterol , thyroid hormone , antiarrhythmic compound , warfarin , metformin clozapine 4 . Treatment vitamin E , calcium , magnesium and/or vitamins concentration superior 149 UI 3 month inclusion 5 . Use drug interfere catacholamine metabolism ( reserpine , amphetamine , inhibitor monoamine oxidase A , methylphenidate , cinnarizine ) month inclusion 6 . Non balance treatment anxiolytic , hypnotic , tranquillizer and/or antidepressant month inclusion 7 . Hypothyroidism thyroxin use 8 . Epilepsy 9 . Psychotic disorder 10 . Pregnancy lactation period 11 . Woman childbearing potential without efficient contraception 12 . Participant therapeutic study month inclusion 13 . Inability receive clear information research 14 . Inability participate totality study 15 . Non affiliation social security ( beneficiary assignee ) 16 . Refusal sign consent form</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Ataxia Oculomotor Apraxia type 1</keyword>
	<keyword>CoQ10</keyword>
	<keyword>hypoalbuminemia</keyword>
</DOC>